Taking people in Spanyolország3. fázis
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.
Key facts
- Where
- Barcelona és Esplugues de Llobregat, SpanyolországSee the 2 sites
- Phase
- 3. fázis
Where in Spanyolország
- Hospital Clinic de BarcelonaBarcelona, SpanyolországTaking people
- Hospital Sant Joan De Deu BarcelonaEsplugues de Llobregat, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Onechain Immunotherapeutics S.L.
- Trial code
- EU 2024-516617-20-00
- Record updated
- 2025. április 11.
- Original description
To monitor patients with primary relapsed/refractory (R/R) CD1a-positive T-ALL/LL who received OC-1 cells, for 15 years following CAR-T infusion to assess the risk of delayed adverse events (AEs).Read full original descriptionShow less
To monitor patients with primary relapsed/refractory (R/R) CD1a-positive T-ALL/LL who received OC-1 cells, for 15 years following CAR-T infusion to assess the risk of delayed adverse events (AEs).
Inclusion: Patients previously treated with at least one fraction of OC-1 cell investigational product; Patient or patient’s legal representative has provided signed and dated informed consent; Patient is able to comply with the study requirements.
Exclusion: None. All patients who have received prior treatment with OC-1 cell investigational product are eligible for this long-term follow up (LTFU) study.